Last mentioned: Mar 10, 2026
Clinical Milestones
Anticipated updates on Phase 1/2 glioblastoma trial progress.
BioFlorida Showcase
Cornerstone Session presentation on innovation in the regional ecosystem.
BioFlorida Showcase
Cornerstone Session presentation on Innovation in South Florida.
Investival Showcase
Presentation at the South Florida Rising Life Science Hub event.
Investival Showcase
Presentation at the South Florida Rising Life Science Hub event.
Conference Invitations
Announced invitations to two major South Florida life sciences showcases.
National Partnering
Presented at BioCom California Global Life Science Partnering Conference.
National Engagement
Presented at BioCom California and BIO Investor Forum to engage global partners.
Myosin Therapeutics has been selected to present its novel nanomotor-dependency platform at two major South Florida life sciences conferences this March. The company is advancing MT-125, a first-in-class inhibitor currently in Phase 1/2 trials for glioblastoma, as it seeks to capitalize on South Florida's emergence as a biotechnology hub.
Myosin Therapeutics has been selected to present its first-in-class nanomotor-dependency platform at two major South Florida life sciences conferences in March 2026. The company is advancing MT-125, a dual NMIIA/IIB inhibitor currently in Phase 1/2 trials for glioblastoma, targeting the physical mechanics of cancer cells to bypass traditional resistance.